3 Big FDA Approvals to Watch For in Q1 2022

Get ready for a deluge of important approval decisions. This year, before April showers get a chance to bring any May flowers, the FDA is expected to make a slew of important approval decisions.

Cancer patients in the U.S. could get some important new treatment options. Shares of the companies involved could put up big gains if the agency delivers the approval decisions investors are hoping for.

Big FDA decisions coming up in the first quarter for Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY) AstraZeneca (NASDAQ: AZN), and Merck (NYSE: MRK) could send their share prices soaring. Here's what to look for.

Continue reading

Source Fool.com